Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study

被引：0
|
作者：
le Coutre, P.
Giles, F. J.
Apperley, J.
Ottmann, O. G.
Larson, R. A.
Haque, A.
Gallagher, N.
Rosti, G.
Cortes, J. E.
Kantarjian, H. M.
机构：
[1] Humboldt Univ, D-10099 Berlin, Germany
[2] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[3] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England
[4] Med Klin III, Frankfurt, Germany
[5] Univ Chicago Hosp, Chicago, IL 60637 USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Orsola Malpighi Univ, Bologna, Italy
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7050
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Nilotinib in accelerated phase chronic myelogenous leukaemia (CML-AP) patients with imatinib-resistance or -intolerance: update of a phase 2 study
    Apperley, J.
    le Coutre, P.
    Giles, F. J.
    Ottmann, O. G.
    Larson, R. A.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 38 - 39
  • [2] Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance
    Le Coutre, Philipp
    Giles, Francis J.
    Apperley, Jane
    Ottmann, Oliver G.
    Gattermann, Norbert
    O'Brien, Stephen G.
    Kuliczkowski, Kazimierz
    Larson, Richard A.
    Kim, Dong-Wook
    Haque, Ariful
    Gallagher, Neil
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 145A - 145A
  • [3] NILOTINIB IN IMATINIB-RESISTANT OR -INTOLERANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE (CML-AP): UPDATE OF A PHASE 2 STUDY
    le Coutre, P.
    Giles, F. J.
    Hochhaus, A.
    Apperley, J.
    Ossenkoppele, G.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 47 - 47
  • [4] Correlation of clinical response to nilotinib with BCR-ABL mutation status in advanced phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance
    Saglio, Giuseppe
    Kim, Dong-Wook
    Hochhaus, Andreas
    Soverini, Simona
    Erben, P.
    Branford, Susan
    Haque, Ariful
    Gallagher, Neil
    Shou, Yaping
    Hughes, Timothy
    Martinelli, G.
    Radich, Jerald
    BLOOD, 2007, 110 (11) : 576A - 577A
  • [5] Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Le Coutre, P. D.
    Giles, F.
    Hochhaus, A.
    Apperley, J. F.
    Ossenkoppele, G.
    Haque, A.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Larson, R.
    Weitzman, A.
    Haque, A.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance
    Kantarjian, Hagop M.
    Hochhaus, Andreas
    Cortes, Jorge
    Martinelli, Giovanni
    Bhalla, Kapil N.
    Giles, Francis J.
    Ossenkoppele, Gert
    Gattermann, Norbert
    Haque, Ariful
    Gallagher, Neil
    Baccarani, Michele
    le Coutre, Philipp
    BLOOD, 2007, 110 (11) : 226A - 226A
  • [8] Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Baccarani, Michele
    de Coutre, Philipp D.
    Haque, Ariful
    Gallagher, Neil J.
    Cortes, Jorge
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1103 - 1103
  • [9] Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis
    Hochhaus, Andreas
    Apperley, Jane F.
    Ossenkoppele, Gert
    Haque, Ariful
    Gallagher, Neil J.
    Baccarani, Michele
    Cortes, Jorge
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 1108 - 1109
  • [10] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
    Hochhaus, A.
    Giles, F.
    Apperely, J.
    Ossenkoppele, G.
    Wang, J.
    Gallagher, N. J.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H.
    Le Coutre, P. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 256 - 256
12345